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ABSTRACT 
Introduction: Serum screening systems are useful in monitoring gastric cancer. The present 
research studied and compared serum levels of pepsinogens, gastrin-17, and Helicobacter 
pylori antibodies in patients with dyspepsia and precancerous lesions by focusing on gastric 
pathology. 
Materials and methods: In this cross-sectional study, patients with dyspepsia symptoms 
from whom gastric biopsy samples were taken during endoscopy entered the present study. 
The biopsy samples were examined using a rapid urease test (RUT) and histopathology study. 
Patients with precancerous lesions were considered the case group (40 individuals) and 
patients with chronic gastritis the control group (88 individuals). Serum pepsinogen I, 
pepsinogen II, gastrin-17, anti-Helicobacter pylori antibodies, and the gene related to 
vacuolatingcytotoxinA(vacA) were measured at a private laboratory in Rasht. The 
information was analyzed by using SPSS 16 and through employing the t-test and the chi-
square test. 
Results: This study included 120 patients with chronic non-atrophic gastritis, 39 with 
metaplasia, 5 with dysplasia, and 6 with neoplasia. No cases of atrophic gastritis were 
observed. The percentages of patients with pepsinogen I levels lower than normal and without 
metaplasia (75.9%)or neoplasia (96.6%) were significantly higher than those with metaplasia 
(24.1%) or neoplasia (3.4%).  
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When the three groups of patients with metaplasia, dysplasia, and atrophic gastritis were 
combined to form a new group (the precancerous group), there were significant differences 
between the case and control groups with respect to levels of pepsinogen I and pepsinogen I/ 
pepsinogen II ratios (p<0.05). The frequencies of patients with lower than normal pepsinogen 
I levels and pepsinogen I/ pepsinogen II ratios in the precancerous group (15 and 20 percent, 
respectively) were higher than those in the chronic gastritis group (1.1 and 5.7 percent, 
respectively) (p<0.05). The mean pepsinogen I levels and pepsinogen I/ pepsinogen II ratio in 
the precancerous group (99.57 and 5.89μg/l, respectively) were smaller compared to those in 
the chronic gastritis group (100.24 and 8.77 μg/l) (p<0.05). No significant differences were 
observed between the groups with respect to pepsinogen II, gastrin-17, or levels of anti-
Helicobacter pylori antibodies. 
Conclusions: Results showed that low pepsinogen I levels and small pepsinogen I to 
pepsinogen II ratios were useful markers for identifying precancerous lesions. It is 
recommended that more research with larger sample volumes be carried out to determine the 
sensitivity and specificity of this test and the possible cutoff values of the mentioned markers. 
Keywords: Pepsinogen, precancerous lesions, gastrin-17 
 
INTRODUCTION 
Gastric cancer is one of the most prevalent types of cancer in the world, about 870,000 new 
cases are diagnosed and 650,000 patients die of it per year, 9.9 percent of all new cases of 
cancer are gastric cancer (1-3), and its incidence rates have rapidly declined in recent years 
(4-7). Part of this decline has resulted from discovering the main risk factors for it (such as 
Helicobacter pylori and other environmental and nutritional hazards), although this decline 
started before Helicobacter pylori was discovered. The decline started in countries with low 
incidence rates including the United States, whereas in countries with high incidence rates the 
decline has shown a slower trend (8). Statistics show that incidence rates of gastric cancer 
vary in different countries ranging from 0.6 casesper 100,000 population in Cameroon to 69.6 
cases per 100,000 population in Korea for men, and from 0.6 cases per 100,000 population in 
Gabon to 30.6 cases per 100,000 population in Peru for women. In general, the highest 
incidence rates were observed in Asia and Latin America (Costa Rica, El-Salvador, and 
Columbia) both for men and for women and in some African countries (Mali, Congo, and 
Ruanda) for women. On the contrary, the lowest incidence rates were found in North America 
and in most African countries both for men and or women (9). Gastric cancer is the fourth 
most frequent type of cancer in the world. Based on a global evaluation, more than 930,000 
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new cases of gastric cancer are diagnosed every year and at least 700,000 people die of it 
annually (10). Although the death rates caused by gastric cancer have noticeably declined in 
many regions during the past 50 years, yet it is still the second cause of death caused by 
cancer in the world (11). Moreover, it is the most prevalent malignancy in Iran with the 
northern and northwestern parts of the country being high risk regions. The incidence rates 
among men and women in Mazandaran and Golestan Provinces are high, and Ardabil 
Province has the highest incidence rate in Iran. Incidence rates of gastric cancer are also high 
in Semnan, Golestan, East Azerbaijan, and Tehran Provinces, whereas Kerman Province in 
southern Iran has lower incidence rates compared to the northern part of the country (10). 
Gastric cancer has several developmental stages: it begins with chronic gastritis and 
progresses to chronic atrophic gastritis, intestinal metaplasia, and to dysplasia. This trend 
usually starts with infection caused by Helicobacter pylori and involves genetic elements and 
environmental factors (12). Endoscopy and biopsy are the gold standard for determining the 
reason for the development of the disease in patients with dyspepsia and provide us with 
information regarding Helicobacter pylori infection, presence of atrophy, intestinal 
metaplasia or dysplasia (and also concerning lesion site) (13). This method is invasive, 
painful, stressful, and expensive and, therefore, rapid, reliable, inexpensive, and non-invasive 
tests for screening and monitoring patients with mild to intermediate symptoms of dyspepsia 
are attracting great interest at present (14). C13 urea breath test and fecal Helicobacter pylori 
antigen are also often used, but they do not provide information about the morphological 
conditions of gastric mucosa (15-16). Recently, use of the ELISA test for measuring serum 
pepsinogen I and II, gastrin-17, and the anti-Helicobacter pylori antibodyIgG as non-invasive 
markers for evaluating functional and morphological conditions of gastric mucosa in patients 
with dyspeptic symptoms has attracted interest (17-18). Pepsinogen I and II are precursors of 
pepsin. Pepsinogen I is mainly secreted by the oxyntic glands and is a proprietary marker of 
the secretory capacity of the stomach body. On the contrary, pepsinogen II is produced by all 
gastric glands (the fundic, cardiac, and pyloric glands) and also by duodenal glands 
(Brunner’s glands) and is strongly influenced by inflammation of the stomach (19-20). These 
precursors are secreted in small quantities inside the gastric lumen and one percent of them 
that are leaked into blood (and can be measured). Gastrin-17 is mainly produced in the gastric 
antrum, is directly secreted into the blood, and is a proprietary marker of G-cell activity (21). 
Since few studies have been carried out in Iran on non-invasive methods of screening for 
precancerous gastric lesions, the present research used non-invasive serological tests 
(measured serum levels of PGI, PGII, the anti-Helicobacter pylori antibody IgG, and gastrin-
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17 and assessed their changes in precancerous lesions and in gastric cancer) instead of 
gastroscopy and biopsy that are performed for patients over 50 years with dyspepsia. 
 
METHODOLOGY 
This descriptive cross-sectional research was conducted in six months and studied patients 
over 50 years who visited a professor of digestive diseases and the gastroenterology clinic at 
Razi Hospital with symptoms of dyspepsia (any feeling of chronic or recurrent pain or 
discomfort in the epigastric region). If the physician thought that these patients exhibited the 
indications, the patients underwent endoscopy and biopsy. During endoscopy, three samples 
were taken from the body, the antrum, and the fundus of the stomach. Moreover, one sample 
was taken for RUT (Rapid Urease Test) to be examined for H. pylori. The samples were 
placed in 10% formalin and sent to the laboratory for pathological tests. The patients were 
divided into a case and a comparison group based on the pathology reports, and those with 
precancerous lesions (such as atrophic gastritis, intestinal metaplasia, and dysplasia) were put 
in the case group and those with mild non-atrophic gastritis in the comparison group. Those 
with gastric cancer were informed of it and referred for treatment continuation and follow-up. 
Personal and general information regarding the patients and the types of their pathology were 
entered into the questionnaire forms, 5 ml blood samples were taken from each patient and 
sent to the laboratory, and the concentrations of pepsinogenI, pepsinogen II, gatrin-17, the 
anti-Helicobacter pylori antibody IgG, and of the Anti-CagA antibodies were measured using 
the ELISA test and the ratios of pepsinogen I to pepsinogen II were calculated. The person 
performing the tests did not know the results of endoscopy or the types of precancerous 
lesions in the patients. 
Ethical considerations: All information in this project was published in general terms 
without naming the patients. Moreover, informed consent was obtained from all patients, and 
those having gastric cancer (shown in the pathology reports) were informed of it and referred 
for treatment continuation and follow-up. 
Inclusion criteria: Patients older than 50 years and without kidney or liver failure who did 
not take PPI, H2 blockers, or antibiotics at least four weeks prior to endoscopy, and had no 
history of gastroduodenal surgery entered the study, and those who could not tolerate 
endoscopy or refused it were excluded from the research. 
The steps taken and the facilities used in the research were as follows 
1. Extraction of the patients’ addresses and telephone numbers from the records kept at 
the pathology laboratories 
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2. Various questionnaires (forms 1 and 2) to record the patients’ particulars and the 
studied variables 
3. Upper endoscopy equipment and materials including 10% Lidocaine spray, upper 
endoscopy equipment together with the necessary accessories, biopsy forceps 
4. Filter paper, formalin solution and the related containers 
5. Laboratory facilities and Dr. Afrah pathological Laboratory 
6. RUT solution 
 
The information was analyzed using SPSS 16 and employing the t-test and the chi-square test 
 
RESULTS 
Among the endoscopic biopsy specimens, there were 120 cases of chronic non-atrophic 
gastritis, 39 of metaplasia, 5 of dysplasia, and 6 of neoplasia, but no cases of atrophic gastritis 
were observed. The most common complaints were stomach ache (50%) and dyspepsia 
(35.9%), and the most frequent endoscopic findings erosive gastropathy (46.1%) and hiatal 
hernia (32%). Twenty eight, 7, 0, and 1 of the patients with chronic gastritis, metaplasia, 
dyspepsia, or neoplasia had lower than normal PGI values, respectively. The numbers of 
patients with lower than normal values of PGI and without metaplasia (22 patients) or without 
neoplasia (28 patients) were significantly higher than among those with metaplasia (7 
patients) or with neoplasia (1 patient) (p<0.05). The numbers of specimens with higher than 
normal PGI values in patients with chronic gastritis, metaplasia, dysplasia, or with neoplasia 
were 58, 18, 1, and 2, respectively.Among patients with chronic gastritis, metaplasia, 
dysplasia, or with neoplasia, the numbers of specimens with PG I/PG II ratios lower than 
normal were 2, 0, 2, and 0, respectively. The number of patients with GI/PGII ratios lower 
than normal among those without neoplasia (Table 2) was significantly larger than those with 
neoplasia (0) ( p<0.05) (Tables 1 and 2). There was a significant relationship between PGI 
and the types of lesions (precancerous lesions).The percentage of specimens with normal PGI 
values was larger in the chronic gastritis group (73.9%) than the precancerous group (67.5%).  
The percentage of PGI values lower than normal was higher (15%) in the precancerous lesion 
group than in the chronic gastritis group (1.1%) (p<0.05) (Table2). The mean PGI value in 
patients with precancerous lesions (99.57) was significantly lower than that among the 
patients with chronic gastritis (100.24) (p<0.05) (Table3). There was a significant relationship 
between PGI/PGII ratios and the types of lesions, and the reduction in this ratio among the 
precancerous group (20%) was greater than the chronic gastritis group (5.7%). The normal 
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PGI/PGII ratio in the chronic gastritis group (92%) was larger than the precancerous group 
(80%) (p<0.05) (Table2). Furthermore, the PGI/PGII ratio in patients with precancerous 
lesions (5.89±3.99) was smaller than in those with non-atrophic gastritis (8.77±4.45) (p<0.05) 
(Table3).There were no significant relationships between the types of lesion and PGII, 
gastrin-17, and the Helicobacter pylori antibody (p<0.05). The mean age in the group with 
precancerous lesions (98±9.5) was significantly higher than group with non-atrophic gastritis 
(65.01±9.2). In patients with smoking history, the percentage with precancerous lesions (10%) 
was smaller than those with non-atrophic gastritis (11.4%), and relationship assessment was 
not performed because the number of smokers in this research was low. In patients with 
drinking history, the percentage of patients with precancerous lesions (0%) was lower than 
those with non-atrophic gastritis (1.1%). In patients with positive RUT history, the percentage 




Table 1. Frequency distribution of chronic gastritis, metaplasia, dysplasia, and neoplasia 









Chronic gastritis 74(57.8) 78(60.9) 109(85.2) 
Metaplasia 27(21.1) 14(10.9) 14(10.9) 
Dysplasia 1(0.8) 3(2.3) 2(1.6) 
Neoplasia 5(3.9) 0(0.0) 2(1.6) 
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Table 2. Comparison of pepsinogen I levels between patients with various lesions shown in 
endoscopy 
PGI More than normal Normal Less than normal P value 










2(28.6) 27(29.3) 65(70.7) 7(24.1) 22(75.9) 0.04 
Dysplasia 0 (0.0) 
 
7(100.0) 5(5.4) 87(94.6) 0(0.0) 29(100.0) 0.36 
Neoplasia 2(28.6) 
 
5(71.4) 2(3.3) 89(96.7) 1(3.4) 28(96.6) 0.009 
 
Table 3. Comparison of pepsinogen II levels in patients with various lesion types shown in 
endoscopy 
PGII More than normal Normal P 
value Lesion type Positive Negative Positive Negative 
Chronic 
gastritis 
62(93.9) 4(6.1) 58(93.5) 4(6.5) 0.60 
Metaplasia 21(31.8) 45(68.2) 18(29.0) 44(71.0) 0.73 
Dysplasia 4(6,1) 62(93.9) 1(1.6) 61(98.4) 0.20 
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Table 4. Comparison of pepsinogen I/pepsinogen II ratios between patients with various 
lesion types shown in endoscopy 
PGI/PGII 
ratio 
More than normal Normal Less than normal P. 
value 
Lesion type Positive Negative positive Negative Positive Negative 
Chronic 
gastritis 
11(84.6) 21(15.4) 107(94.7) 6(5.3) 2(100.0) 0(0.0) 0.34 
Metaplasia 7(53.8) 6946.2) 32(28.3) 81971.7) 0(0.0) 2(100.0) 0.107 
Dysplasia 13(100.0) 0(0.0) 108(95.6) 5(5.4) 2(100.0) 0(0.0) 0.70 
Neoplasia 3(23.1) 10(76.9) 3(2.7) 110(97.3) 0(0.0) 2(100.0) 0.004 
 
Since the sample number was small in many cells, the metaplasia and dysplasia lesions were 
combined to make results of the analysis meaningful, and this new group was compared with 
the group of chronic gastritis lesions. 
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Table 5. Comparison of frequency distributions of PGI, PGII, PGI/PGII, gastrin-17, and anti-
Helicobacter pylori antibody between patients with precancerous lesions and those in the non-










PG I Less than 
normal 
1(1.1%) 6(15%) 0.005 








PG I/PG II Less than 
normal 
5(5.7%) 8(20%) 0.03 




Gastrin-17 Less than 
normal 
1(1.1%) 0(0.0%) 0.777 






Positive 00(0.0%) 2(5%) 0.03 
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Table 6. Comparison of the means of pepsinogen I, pepsinogen II, pepsinogen I/pepsinogen 
II, gastrin-17, anti HP, anti-CagA antibodies in patients with precancerous lesions and those 
with non-atrophic gastritis 
Group Mean (standard 
deviation) 
P. value 








































In the present research, the PG I levels in patients with chronic gastritis and without it and in 
patients with dysplasia and without it were not significantly different, but its levels in patients 
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with and without metaplasia and also in patients with and without neoplasia were significantly 
different. PG I levels were only different in precancerous metaplastic lesions and this factor 
did not exhibit significant differences in other precancerous lesions (atrophic gastritis or 
dysplasia). PGI levels and PG I/PG II ratios in the group of patients with precancerous lesions 
were significantly lower than the group with non-atrophic gastritis. Various similar studies 
with different designs have been conducted throughout the world. Cao Qet al. (2007) showed 
that PGI and PG I/Pg II ratiosin patients with atrophic gastritis and gastric cancer declined 
compared to the healthy group. They concluded that increased serum levels of G-17 and 
reduced PG I levels and PG I/PG II ratioscould be employed for screening (22).Germanaet al. 
(2005) noticed that serum levels of PG I, and PG I/PGII ratios, in patients with atrophic 
gastritis were significantly lower compared to patients with chronic non-atrophic gastritis 
(23). In another study conducted in Japan in 2009, it was suggested that PG I, PG II, G 17, 
and HP IgG could be used to distinguish healthy people from those with atrophic gastritis 
(24). Kwak et al. (2010) in South Korea found an inverse correlation between mean PG I 
levels and PG I/PG II ratios and the stages of gastritis: the mean PG I levels and PG I/PG II 
ratios significantly declined with advancing gastritis stages (from stage 0 to high-stage 
gastritis) (25).In Japan, Ubukata H et al. (2010) carried out a study on patients that were 
supposed to undergo gastrostomy. They suggested that gastric cancer in pepsinogen negative 
people may have higher malignant potential compared to pepsinogen positive patients (26). In 
the United States, Abnet CC et al. (2011) showed in their case-control research that plasma 
PG I concentrations lower than 50ng/ml and plasma PG II concentration higher than 6.6 
ng/mlhad significant relationships with higher risk of gastric cancer. They also noticed that 
PG I/PG II ratios had a linear relationship with gastric cancer (27). In Chile, a study on 
atrophic gastritis patients revealed that PG I serum levels of lower than 61.5 μg/ml, PG I/PG 
II ratios smaller than 2.2, and gastrin concentrations higher than 13.3pmol/l had high 
accuracies (91-100%) and low sensitivity (56-78%) in detecting atrophy of the upper part of 
the stomach (28). In research carried out in Finland in 2002 to see if it was possible to 
diagnose atrophic gastritis and determine its site without performing endoscopy, it was 
concluded that low serum gastrin 17 and PG I levels were biomarkers for the antrum and body 
of the stomach (29). In Peru, Colarossi et al. (2011) conducted a case-control study on 
patients with atrophic gastritis and used people without this disease as the control group. They 
studied and compared serological profiles of PG I and PG I/PG II ratios and found that there 
were no differences between the case and control groups with respect to the above mentioned 
markers, and pepsinogen and gastrin tests were not appropriate for atrophy (30).In the present 
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research, mean gastrin 17 and PG II concentrations in patients with precancerous lesions were 
higher than those in patients with atrophic gastritis. In a study carried out in China in 2007, 
gastrin 17 levels in the atrophic gastritis group 9 that also had dysplasia) was higher than the 
group without dysplasia. They suggested that lesion site was an important factor that 
influenced gastrin 17 levels (31). Zhanget al. (2006) showed that PG II levels in chronic 
atrophic gastritis and in gastric cancer were significantly higher than in healthy groups. 
Moreover, PG I/PG II ratios in patients with chronic atrophic gastritis and gastric cancer were 
significantly lower than the other groups (32). Haj Sheykholeslami et al. (2008) carried out a 
study in Tehran and showed that PG II was a suitable marker in screening for any gastritis 
from normal mucosa, but PG I, PG I/PGII, gastrin 17, or their combination were not able to 




The present research clearly showed that there were significant differences between patients 
with precancerous lesions and those with chronic gastritis with respect to PG I levels and the 
PG I/PG II ratios. No significant differences were observed between patients with 
precancerous lesions and those with chronic gastritis with respect to other markers such as PG 
II, gastrin 17, and Helicobacter pylori antibodies. 
 
SUGGESTIONS 
Considering the high prevalence of gastric cancer, the fact that it can be treated in its early 
stages and the importance of its early diagnosis in high risk patients, use of noninvasive 
methods acceptable to patients such as serum markers is very important. We recommend that 
sensitivity and specificity of pepsinogens for diagnosis shouldbe determined in future studies 
with more in depth analysis of the data.  
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